| Type | Sociedad Anónima |
|---|---|
| Traded as | BMAD: GRF |
| Industry | Pharmaceuticals, chemicals |
| Founded | 1940 |
| Headquarters | Barcelona, Spain |
| Key people | Víctor Grifols (Chairman and CEO) |
| Products | Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals |
| Revenue | €990.7 million (2010)[1] |
| Operating income | €209.7 million (2010)[1] |
| Profit | €115.5 million (2010)[1] |
| Total assets | €1.889 billion (end 2010)[1] |
| Total equity | €707.4 million (end 2010)[1] |
| Employees | 5,970 (average, 2010)[1] |
| Website | www.grifols.com |
Grifols, S.A. is a Spanish-based multinational pharmaceutical and chemical company. Principally a producer of blood plasma-based products, a field in which it is the European leader,[2] the company also supplies devices, instruments and reagents for clinical testing laboratories.
Contents |
Grifols is a major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.
In 2007 the company had 3.6 million litres per year of blood fractionation capacity from two plants, one at Parets del Vallès near Barcelona in Spain (2.1 million litres per year) and another in Los Angeles (1.5 million litres but being expanded to 2.2 million litres). In the United States the company owns 80 plasmapheresis centres, where it collects around 2 million litres of plasma per year.
Grifols was listed on the Madrid Stock Exchange in May 2006.[3] The stock became part of the IBEX 35 index in January 2008.
Grifols was founded in 1940 by Dr José A. Grifols Roig, a hematologist and scientist. Dr Grifols was the first researcher to publish the plasmapheresis procedure in 1951. The company introduced its liquid IVIG product into the European market in the mid-1990s. In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic as the basis of its American expansion.
On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.[4]